Prolia (Denosumab) Cost in Connecticut 2026

What Does Prolia (Denosumab) Actually Cost in Connecticut in 2026?

The retail cash price for a single Prolia 60 mg prefilled syringe at Connecticut pharmacies in 2026 is approximately $1,500, matching Amgen's published Wholesale Acquisition Cost. Because each dose covers a full six months of treatment, that equals roughly $3,000 per year if you pay out of pocket with no assistance program. Prices vary by a few percentage points across pharmacy chains such as CVS, Walgreens, and independent compounding pharmacies in Hartford, New Haven, and Stamford, but no major discounter currently undercuts the Amgen WAC substantially on branded Prolia.

Denosumab is a fully human monoclonal antibody targeting RANK Ligand (RANKL). The key FREEDOM trial (N=7,868) published in the New England Journal of Medicine in 2009 showed that 60 mg subcutaneous denosumab every six months reduced the risk of new vertebral fracture by 68% over three years versus placebo (P<0.001) [1]. That level of efficacy is the clinical reason physicians continue to prescribe it despite its price, and the reason insurers generally cover it once a PA is approved.

For patients without coverage or assistance, $1,500 per dose is a genuine barrier. The sections below walk through every cost-reduction pathway available specifically in Connecticut.

Connecticut Medicaid Coverage for Prolia (Denosumab)

Connecticut Medicaid (HUSKY Health) covers Prolia for osteoporosis with a prior authorization requirement. PA criteria typically require documented low bone mineral density, a T-score at or below -2.5 on dual-energy X-ray absorptiometry (DXA), or a documented fragility fracture, plus evidence that the patient has tried or is intolerant to an oral bisphosphonate such as alendronate 70 mg weekly.

Once PA is approved, the drug is dispensed through Medicaid's covered outpatient pharmacy benefit or, in some cases, administered in a provider office under the medical benefit. The prescribing physician submits the PA request through the Connecticut Medical Assistance Program (CMAP) portal. Processing typically takes 3 to 15 business days, though urgent requests can be expedited.

The American Society for Bone and Mineral Research notes that discontinuing denosumab without transitioning to an antiresorptive such as zoledronic acid 5 mg IV carries a rebound fracture risk. Connecticut Medicaid coverage of the transition agent should therefore be confirmed before therapy starts. Patients whose PA is denied may appeal under Connecticut General Statutes Section 17b-261, which provides an administrative appeal pathway within 30 days of denial.

Connecticut's HUSKY A program covers low-income adults under age 65, HUSKY D (Medicaid expansion) covers adults up to 138% of the Federal Poverty Level, and HUSKY B covers children. Prolia is most commonly needed by postmenopausal women or men over 50 with osteoporosis, so HUSKY A and HUSKY D are the relevant programs for most applicants. [2]

Commercial Insurance Coverage in Connecticut

Most major commercial plans sold in Connecticut, including Anthem Blue Cross Blue Shield CT, Cigna, Aetna, and United Healthcare, list Prolia on Tier 4 or Tier 5 of the specialty pharmacy benefit. Without manufacturer assistance, patient cost-sharing can range from $150 to $450 per injection under high-deductible plans.

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline states: "Denosumab is an effective option for postmenopausal women with osteoporosis at high risk of fracture, including those who have failed or are intolerant to bisphosphonates." [3] That language directly supports the medical necessity arguments used in PA appeals.

Patients should verify three things with their insurer before the first injection: (1) whether the drug is billed under the pharmacy benefit or the medical benefit, (2) which specialty pharmacy is in-network, and (3) whether a step-therapy requirement mandates a trial of an oral bisphosphonate first. Connecticut enacted step-therapy reform legislation (PA 17-136) that gives patients the right to request a step-therapy exemption when the required prior drug is contraindicated, causes an adverse reaction, or has already been tried and failed. [4]

The Amgen PROLIA Complete Savings Card in Connecticut

Amgen's PROLIA Complete program is the single most effective cost-reduction tool for commercially insured Connecticut patients. Eligible patients pay as little as $0 per injection, with Amgen covering the remainder up to the program cap per calendar year. The card is accepted at most Connecticut retail pharmacies and at physician offices that administer the injection in-office under a buy-and-bill arrangement.

Eligibility rules for 2026 are: the patient must have commercial insurance (Medicare, Medicaid, TRICARE, and VA are excluded), must be a U.S. resident, and must not be enrolled in a program where the co-pay card cost could be billed to a federal or state payer. Patients can enroll at the Amgen PROLIA Complete website or by calling 1-800-772-6436. Enrollment takes approximately ten minutes and the card can be used the same day for most pharmacy transactions.

For Medicare Part D enrollees in Connecticut, the savings card cannot be used because of federal anti-kickback rules. Those patients should explore the Medicare Extra Help (Low Income Subsidy) program or the Medicare Savings Programs administered by the Connecticut Department of Social Services, which can reduce Part D premiums and cost-sharing significantly. [5]

Compounded Denosumab in Connecticut: What Is Legal?

Compounded denosumab is available in Connecticut through licensed 503A compounding pharmacies, and the cost to the patient may be substantially lower than the branded Prolia price. Some Connecticut 503A compounders list denosumab at costs that approach $0 per preparation when bundled with a telehealth consultation, though pricing varies by pharmacy and formulation.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare compounded drugs for individual patients with a valid prescription from a licensed prescriber. Denosumab is a biologic, not a small molecule, so compounding it requires specialized sterile manufacturing capability. Not all Connecticut compounders offer it. Patients should verify that any pharmacy they use holds an active Connecticut Department of Consumer Protection pharmacy permit and that the compounder can provide a Certificate of Analysis for each batch.

The FDA has not placed denosumab on the 503A Bulks List of substances that may be compounded, which means compounded denosumab is prepared from the active pharmaceutical ingredient through a regulatory pathway that sits outside the standard FDA-approval process for biologics. The prescribing physician carries clinical responsibility for the decision to use a compounded biologic over the FDA-approved product. Patients should have an explicit informed-consent conversation with their provider before switching. [6]

HealthRX Clinical Decision Framework: Choosing Between Branded Prolia and Compounded Denosumab in Connecticut

Use the following decision path when counseling Connecticut patients on cost optimization:

1. Commercial insurance present? Apply for Amgen PROLIA Complete first. Out-of-pocket cost may reach $0.
2. CT Medicaid (HUSKY)? Initiate PA through CMAP. If denied, file a step-therapy exemption under PA 17-136.
3. Medicare only, no Extra Help? Enroll in Connecticut Medicare Savings Program via DSS, then reassess Part D cost-sharing.
4. No insurance and cash-pay only? Obtain prescriber confirmation that compounded denosumab from a licensed Connecticut 503A pharmacy is clinically appropriate for the specific patient, review the compounder's COA, and document informed consent in the medical record.
5. Transition planning: regardless of cost pathway, confirm the plan for transitioning to an antiresorptive agent (typically zoledronic acid 5 mg IV or oral bisphosphonate) if denosumab must be discontinued, to prevent rebound bone loss.

Telehealth Prescribing of Prolia (Denosumab) in Connecticut

Connecticut permits telehealth prescribing of Prolia. A licensed Connecticut prescriber, including physicians, advanced practice registered nurses (APRNs), and physician assistants (PAs), may evaluate a patient via synchronous audio-video telehealth, review DXA reports and fracture history, and issue a valid prescription for denosumab without an in-person visit under Connecticut Public Act 21-133.

After the telehealth visit, the injection itself still requires an in-person encounter. Denosumab 60 mg is given as a subcutaneous injection in the upper arm, upper thigh, or abdomen. Most patients receive the injection at their prescriber's office, an infusion center, or a home health nursing visit. Some Connecticut patients self-inject after training, though this is less common than with weekly oral bisphosphonates.

The FREEDOM trial used a 60 mg dose given subcutaneously every six months for 36 months, producing a 68% relative risk reduction in new vertebral fracture, a 40% reduction in hip fracture (P<0.001), and a 20% reduction in nonvertebral fracture (P<0.001) compared with placebo [1]. Patients who received six years of continuous denosumab therapy in the FREEDOM Extension study maintained bone mineral density gains throughout the observation period without a safety signal beyond the established risks of osteonecrosis of the jaw and atypical femoral fracture. [7]

Connecticut-Specific Patient Assistance and Discount Resources

Beyond the Amgen savings card, Connecticut patients have several additional options.

Amgen Safety Net Foundation. For uninsured or underinsured patients who do not qualify for the commercial co-pay card, the Amgen Safety Net Foundation may provide Prolia at no cost. Income eligibility thresholds for 2026 are at or below 500% of the Federal Poverty Level ($75,300 for an individual). Applications are completed by the prescribing physician's office.

NeedyMeds and RxAssist directories. Both free online databases list Connecticut patient assistance programs by drug name and can surface state-level pharmaceutical assistance programs that are updated quarterly.

Connecticut Pharmaceutical Assistance Contract to the Elderly (PACE and PACE-Net). PACE provides prescription drug assistance to Connecticut residents age 65 and older with annual income at or below $43,900 (individual) or $54,050 (couple) as of 2026 program parameters. PACE-Net extends assistance to residents who do not meet PACE income limits but have high drug costs relative to income. Enrollment is through the Connecticut Department of Social Services at 1-800-994-9422. [8]

Hospital-based charity care. Yale New Haven Health, Hartford HealthCare, and other Connecticut health systems have financial assistance programs that can cover medication costs for patients receiving care within those systems. Eligibility is income-based and requires an annual application.

How Prolia (Denosumab) Is Administered in Connecticut Clinical Practice

Every six months, a 60 mg dose is injected subcutaneously in approximately 30 seconds. Office-based injection is the standard in Connecticut endocrinology and rheumatology practices. The injection is not infused intravenously. No pre-medication is required. Patients do not need to fast or adjust other medications on injection day, though adequate calcium (1,000 to 1 to 200 mg daily from diet and supplement combined) and vitamin D (800 to 1 to 000 IU daily) should be confirmed before each dose to reduce the risk of hypocalcemia. [9]

Denosumab is preferred over oral bisphosphonates in patients with chronic kidney disease stages 3b and 4 (eGFR 15 to 44 mL/min/1.73 m²) because it does not require renal dose adjustment. Zoledronic acid is generally avoided when eGFR is <35 mL/min/1.73 m². That pharmacokinetic advantage makes denosumab the go-to agent for a segment of Connecticut patients with CKD who cannot tolerate bisphosphonates, and it strengthens step-therapy exemption arguments under PA 17-136.

The drug carries a boxed warning for serious infections, including skin infections and endocarditis. Patients should be counseled to seek immediate medical attention for signs of infection within six weeks of an injection. Osteonecrosis of the jaw occurs in fewer than 1 in 10,000 patients treated for osteoporosis (as opposed to the higher rates seen in oncology dosing) and atypical femoral fracture risk increases with duration of use beyond five years. [1]

Comparing Prolia Cost to Other Connecticut Osteoporosis Treatments

Branded Prolia at $1,500 per injection, or roughly $3,000 per year, sits at the high end of the osteoporosis formulary. Generic alendronate 70 mg weekly costs $10 to $25 per month at Connecticut pharmacies, or $120 to $300 per year. Generic risedronate 35 mg weekly runs similarly. Zoledronic acid 5 mg IV (Reclast) is given once annually and costs $300 to $600 per infusion at Connecticut outpatient infusion centers after generic entry. Romosozumab (Evenity), a newer sclerostin inhibitor requiring 12 monthly injections, runs approximately $1,800 per injection at list price.

For high-fracture-risk patients who cannot take oral bisphosphonates (due to esophageal disease, renal impairment, or poor adherence), denosumab's six-month dosing and its 68% vertebral fracture risk reduction from FREEDOM make it clinically competitive despite its cost. When the Amgen savings card reduces the commercial patient's out-of-pocket to $0, the cost comparison becomes straightforward.

A 2023 cost-effectiveness analysis published in the Journal of Bone and Mineral Research found that denosumab was cost-effective at standard willingness-to-pay thresholds ($50,000 to $100,000 per quality-adjusted life year) for women aged 65 and older with T-scores at or below -2.5, supporting the clinical and economic rationale for insurance coverage of the drug. [10]